Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 0.98 |
| ▸ | ADRB1 | P08588 | 20/20 | 0.98 |
| ▸ | ADRB3 | P13945 | 20/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | HTR1A | P08908 | 1/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | HTR1B | P28222 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3395219 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL185829 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL185830 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL30480361 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL4808416 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL4808428 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL5265393 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL3958888 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| Sulfamate SCHEMBL4800865 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4HTR1A | |
| SCHEMBL4805616 | 0.98 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649209-B2 | Crystalline freebase forms of a biphenyl compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-05-16 | — | — | US | disclosed |
| US-20220306580-A1 | CRYSTALLINE FREEBASE FORMS OF A BIPHENYL COMPOUND | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2022-09-29 | — | — | US | disclosed |
| US-20220306579-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-29 | — | — | US | disclosed |
| US-11390603-B2 | Crystalline forms of a biphenyl compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-07-19 | — | — | US | disclosed |
| CN-110713489-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-110183440-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-04-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649209-B2 | Crystalline freebase forms of a biphenyl compound | TBCB, FFAR1, CRYAB | ADRB2 1997/4885ADRB1 865/4885ADRB3 1652/4885 |
| US-11390603-B2 | Crystalline forms of a biphenyl compound | FFAR1, FFAR4, FFAR3 | ADRB2 2730/4885ADRB1 1439/4885ADRB3 2164/4885 |
| US-20220306579-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | ADRB2 14/4885ADRB1 7/4885ADRB3 13/4885 |
| US-20220306580-A1 | CRYSTALLINE FREEBASE FORMS OF A BIPHENYL COMPOUND | TBCB, FFAR1, CRYAB | ADRB2 1997/4885ADRB1 865/4885ADRB3 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.